| Literature DB >> 28775045 |
Boris Duchemann1,2, Isabella Annesi-Maesano3, Camille Jacobe de Naurois4, Shreosi Sanyal3, Pierre-Yves Brillet2,5, Michel Brauner5, Marianne Kambouchner6, Sophie Huynh7, Jean Marc Naccache8, Raphael Borie9, Jacques Piquet10, Arsène Mekinian11, Jerôme Virally7, Yurdagul Uzunhan1,2, Jacques Cadranel8, Bruno Crestani9, Olivier Fain11, Francois Lhote12, Robin Dhote13, Nathalie Saidenberg-Kermanac'h14, Paul-André Rosental15, Dominique Valeyre1,2, Hilario Nunes16,2.
Abstract
The objective of the study was to estimate the prevalence and incidence of interstitial lung diseases (ILDs) in Seine-Saint-Denis, a multi-ethnic county of Greater Paris, France.Patients with ILDs were identified between January and December 2012 by using several sources; all potentially involved medical specialists from public and private hospitals, community-based pulmonologists and general practitioners, and the Social Security system. Diagnoses were validated centrally by an expert multidisciplinary discussion.1170 ILD cases were reported (crude overall prevalence: 97.9/105 and incidence: 19.4/105/year). In the 848 reviewed cases, the most prevalent diagnoses were sarcoidosis (42.6%), connective tissue diseases associated ILDs (CTDs-ILDs) (16%), idiopathic pulmonary fibrosis (IPF) (11.6%), and occupational ILDs (5.0%), which corresponded to a crude prevalence of 30.2/105 for sarcoidosis, 12.1/105 for CTDs-ILDs and 8.2/105 for IPF. The prevalence of fibrotic idiopathic interstitial pneumonias, merging IPF, nonspecific interstitial pneumonia and cases registered with code J84.1 was 16.34/105 An adjusted multinomial model demonstrated an increased risk of sarcoidosis in North Africans and Afro-Caribbeans and of CTDs-ILDs in Afro-Caribbeans, compared to that in Europeans.This study, with a comprehensive recruitment and stringent diagnostic criteria, emphasises the importance of secondary ILDs, particularly CTDs-ILDs and the relatively low prevalence of IPF, and confirms that sarcoidosis is a rare disease in France.Entities:
Mesh:
Year: 2017 PMID: 28775045 DOI: 10.1183/13993003.02419-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671